Vira Therapeutics
Innsbruck, Tirol, Austria
About Vira Therapeutics
ViraTherapeutics develops highly potent anti-cancer therapeutics based on oncolytic (cancer-destroying) viruses. Our proprietary oncolytic virus, VSV-GP, efficiently destroys cancer cells, while leaving normal tissues unharmed. ViraTherapeutics currently performs preclinical safety and efficacy studies for VSV-GP and aims to conduct first clinical trials in cancer patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $4.0M
- Funding stage: M&A
- Last round: Series A (Jun 2015)
- Website: viratherapeutics.com
- Phone: +43512272061
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/vira-therapeutics-2484452 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.